The evolution of automation in biopharmaceutical development is rapidly advancing, with new technologies like robotic process automation (RPA) and AI making significant impacts. In a recent article in BioPharm International, ICON’s Dr Ronan Fox discusses how these tools are being used to enhance quality, efficiency, and speed in drug development and manufacturing. Read the full article here: https://ow.ly/KGch50T8lIp #Biopharmaceuticals #Automation #AI #RPA #LifeSciences #ClinicalResearch #ICONplc
About us
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
- Website
-
http://www.iconplc.com
External link for ICON plc
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Dublin
- Type
- Public Company
- Specialties
- Medical Device, Therapeutics, Government and Public Health Solutions, Clinical Research Services, Commercialisation and Outcomes, Oncology, Value Based Healthcare, Clinical Trials, Patient Recruitment, Innovation, Regulatory Affairs, Strategic Consulting, Medical Affairs, and Global Patient Insights & Engagement
Locations
Employees at ICON plc
Updates
-
As China’s healthcare landscape continues to evolve, the 2024 NRDL introduces crucial changes that could reshape the pharmaceutical industry. The emphasis on reliable drug supply and the integration of manufacturer credentials highlight a patient-centric approach. Explore our blog for an in-depth analysis of the 2024 NRDL and its implications. https://ow.ly/iOz350T1ZuF
-
Oligonucleotide therapeutics are an emerging field with over a dozen new oligonucleotide drugs approved globally since 2016. This well-established chemical process for synthesizing oligonucleotides gives access to ‘large small’ molecules between 5000 to 20,000 Daltons and positions this therapeutic modality between small molecules and biologicals. Assessing the quality and specifications is often a challenge in this regulatory grey area, given the fact that ICH guidelines consider this modality as a chemical entity while sharing properties with biologics. Tune into our webinar to hear our experts discuss CMC IMP considerations for Oligonucleotides, including the critical quality attributes (CQAs) and critical process parameters (CPPs) in oligonucleotide drug product development, plus guidance on setting and meeting specifications to ensure quality and compliance when progressing into early phase studies. Register here: https://ow.ly/W56P50SMUpF
-
Join us on 17 September at 11:00 EST for an in-depth webinar on survival analysis techniques and lessons learned in handling immature data. This session will cover the fundamentals of survival analysis, recent applications, and challenges in modelling various outcomes. Click here to register today: https://ow.ly/ZkbY50SKHAT #HealthEconomics #SurvivalAnalysis #Webinar #Pharma
-
One way to bring the promise of precision health to all humans is through precision measurement. Effective trials start with the right measures — those that matter the most to the patient’s quality of life. Read insights in our blog: https://ow.ly/oh2950T2KYW #PrecisionHealth #ClinicalTrials #PatientCentric
-
Hear our Medical Device experts explore FDA warning letters, recalls and the benefits of early clinical and regulatory engagement in episode one of this informative podcast series. https://ow.ly/7eSq50T6hOn
-
At ICON, our passion for advancing new medicines and treatments is driven by deeply personal stories that connect us to our mission. MyWhy is our platform to share these stories - stories that inspire, give us purpose, and foster growth. Our latest episode features our colleagues sharing their stories and reminding us how vital our work is to improving patients and their family’s lives.
-
This 17 – 18 September you will have the opportunity to hear ICON experts unveil the latest innovations to modernize clinical trials. Join us at the Loews Philadelphia Hotel . https://ow.ly/J3Ur50SZ7YB
-
ICON is strengthening communities and increasing diversity in STEM by partnering with Trinity College Dublin, University of Limerick in Ireland and Thurgood Marshall College Fund in the US to provide scholarships for STEM course students. Learn more in the ICON Cares report: https://ow.ly/27lr50T8oui #ICONCares #DIB #EqualOpportunities #STEM #SDG10 #SDG4
-
For any new combination vaccine to be adopted, public health decision makers rely on health technology assessments to systematically assess the impact of introducing a new health technology from a multidisciplinary perspective. Discover more. https://ow.ly/kPtz50SXxzh